[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Biosimilar Insulin-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

December 2017 | 132 pages | ID: B1A8EC59F0AEN
MIReports Co., Limited

US$ 3,680.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Summary

Biosimilar Insulin-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Biosimilar Insulin industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Biosimilar Insulin 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Biosimilar Insulin worldwide and market share by regions, with company and product introduction, position in the Biosimilar Insulin market
Market status and development trend of Biosimilar Insulin by types and applications
Cost and profit status of Biosimilar Insulin, and marketing status
Market growth drivers and challenges

The report segments the global Biosimilar Insulin market as:

Global Biosimilar Insulin Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa

Global Biosimilar Insulin Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Rapid Acting Insulins
Short Acting Insulins
Intermediate Insulins
Long Lasting Insulins

Global Biosimilar Insulin Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital
Clinic
Medical Center

Global Biosimilar Insulin Market: Manufacturers Segment Analysis (Company and Product introduction, Biosimilar Insulin Sales Volume, Revenue, Price and Gross Margin):

Pfizer
Biogenomics
Eli Lilly
Gan&Lee Pharmaceuticals
Geropharm
Julphar Gulf Pharmaceutical Industries
Paras Biopharmaceuticals
Samsung Bioepis
Sedico
Wockhardt
Teva Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

CHAPTER 1 OVERVIEW OF BIOSIMILAR INSULIN

1.1 Definition of Biosimilar Insulin in This Report
1.2 Commercial Types of Biosimilar Insulin
  1.2.1 Rapid Acting Insulins
  1.2.2 Short Acting Insulins
  1.2.3 Intermediate Insulins
  1.2.4 Long Lasting Insulins
1.3 Downstream Application of Biosimilar Insulin
  1.3.1 Hospital
  1.3.2 Clinic
  1.3.3 Medical Center
1.4 Development History of Biosimilar Insulin
1.5 Market Status and Trend of Biosimilar Insulin 2013-2023
  1.5.1 Global Biosimilar Insulin Market Status and Trend 2013-2023
  1.5.2 Regional Biosimilar Insulin Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Development of Biosimilar Insulin 2013-2017
2.2 Sales Market of Biosimilar Insulin by Regions
  2.2.1 Sales Volume of Biosimilar Insulin by Regions
  2.2.2 Sales Value of Biosimilar Insulin by Regions
2.3 Production Market of Biosimilar Insulin by Regions
2.4 Global Market Forecast of Biosimilar Insulin 2018-2023
  2.4.1 Global Market Forecast of Biosimilar Insulin 2018-2023
  2.4.2 Market Forecast of Biosimilar Insulin by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

3.1 Sales Volume of Biosimilar Insulin by Types
3.2 Sales Value of Biosimilar Insulin by Types
3.3 Market Forecast of Biosimilar Insulin by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Global Sales Volume of Biosimilar Insulin by Downstream Industry
4.2 Global Market Forecast of Biosimilar Insulin by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

5.1 North America Biosimilar Insulin Market Status by Countries
  5.1.1 North America Biosimilar Insulin Sales by Countries (2013-2017)
  5.1.2 North America Biosimilar Insulin Revenue by Countries (2013-2017)
  5.1.3 United States Biosimilar Insulin Market Status (2013-2017)
  5.1.4 Canada Biosimilar Insulin Market Status (2013-2017)
  5.1.5 Mexico Biosimilar Insulin Market Status (2013-2017)
5.2 North America Biosimilar Insulin Market Status by Manufacturers
5.3 North America Biosimilar Insulin Market Status by Type (2013-2017)
  5.3.1 North America Biosimilar Insulin Sales by Type (2013-2017)
  5.3.2 North America Biosimilar Insulin Revenue by Type (2013-2017)
5.4 North America Biosimilar Insulin Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

6.1 Europe Biosimilar Insulin Market Status by Countries
  6.1.1 Europe Biosimilar Insulin Sales by Countries (2013-2017)
  6.1.2 Europe Biosimilar Insulin Revenue by Countries (2013-2017)
  6.1.3 Germany Biosimilar Insulin Market Status (2013-2017)
  6.1.4 UK Biosimilar Insulin Market Status (2013-2017)
  6.1.5 France Biosimilar Insulin Market Status (2013-2017)
  6.1.6 Italy Biosimilar Insulin Market Status (2013-2017)
  6.1.7 Russia Biosimilar Insulin Market Status (2013-2017)
  6.1.8 Spain Biosimilar Insulin Market Status (2013-2017)
  6.1.9 Benelux Biosimilar Insulin Market Status (2013-2017)
6.2 Europe Biosimilar Insulin Market Status by Manufacturers
6.3 Europe Biosimilar Insulin Market Status by Type (2013-2017)
  6.3.1 Europe Biosimilar Insulin Sales by Type (2013-2017)
  6.3.2 Europe Biosimilar Insulin Revenue by Type (2013-2017)
6.4 Europe Biosimilar Insulin Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

7.1 Asia Pacific Biosimilar Insulin Market Status by Countries
  7.1.1 Asia Pacific Biosimilar Insulin Sales by Countries (2013-2017)
  7.1.2 Asia Pacific Biosimilar Insulin Revenue by Countries (2013-2017)
  7.1.3 China Biosimilar Insulin Market Status (2013-2017)
  7.1.4 Japan Biosimilar Insulin Market Status (2013-2017)
  7.1.5 India Biosimilar Insulin Market Status (2013-2017)
  7.1.6 Southeast Asia Biosimilar Insulin Market Status (2013-2017)
  7.1.7 Australia Biosimilar Insulin Market Status (2013-2017)
7.2 Asia Pacific Biosimilar Insulin Market Status by Manufacturers
7.3 Asia Pacific Biosimilar Insulin Market Status by Type (2013-2017)
  7.3.1 Asia Pacific Biosimilar Insulin Sales by Type (2013-2017)
  7.3.2 Asia Pacific Biosimilar Insulin Revenue by Type (2013-2017)
7.4 Asia Pacific Biosimilar Insulin Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

8.1 Latin America Biosimilar Insulin Market Status by Countries
  8.1.1 Latin America Biosimilar Insulin Sales by Countries (2013-2017)
  8.1.2 Latin America Biosimilar Insulin Revenue by Countries (2013-2017)
  8.1.3 Brazil Biosimilar Insulin Market Status (2013-2017)
  8.1.4 Argentina Biosimilar Insulin Market Status (2013-2017)
  8.1.5 Colombia Biosimilar Insulin Market Status (2013-2017)
8.2 Latin America Biosimilar Insulin Market Status by Manufacturers
8.3 Latin America Biosimilar Insulin Market Status by Type (2013-2017)
  8.3.1 Latin America Biosimilar Insulin Sales by Type (2013-2017)
  8.3.2 Latin America Biosimilar Insulin Revenue by Type (2013-2017)
8.4 Latin America Biosimilar Insulin Market Status by Downstream Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

9.1 Middle East and Africa Biosimilar Insulin Market Status by Countries
  9.1.1 Middle East and Africa Biosimilar Insulin Sales by Countries (2013-2017)
  9.1.2 Middle East and Africa Biosimilar Insulin Revenue by Countries (2013-2017)
  9.1.3 Middle East Biosimilar Insulin Market Status (2013-2017)
  9.1.4 Africa Biosimilar Insulin Market Status (2013-2017)
9.2 Middle East and Africa Biosimilar Insulin Market Status by Manufacturers
9.3 Middle East and Africa Biosimilar Insulin Market Status by Type (2013-2017)
  9.3.1 Middle East and Africa Biosimilar Insulin Sales by Type (2013-2017)
  9.3.2 Middle East and Africa Biosimilar Insulin Revenue by Type (2013-2017)
9.4 Middle East and Africa Biosimilar Insulin Market Status by Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILAR INSULIN

10.1 Global Economy Situation and Trend Overview
10.2 Biosimilar Insulin Downstream Industry Situation and Trend Overview

CHAPTER 11 BIOSIMILAR INSULIN MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

11.1 Production Volume of Biosimilar Insulin by Major Manufacturers
11.2 Production Value of Biosimilar Insulin by Major Manufacturers
11.3 Basic Information of Biosimilar Insulin by Major Manufacturers
  11.3.1 Headquarters Location and Established Time of Biosimilar Insulin Major Manufacturer
  11.3.2 Employees and Revenue Level of Biosimilar Insulin Major Manufacturer
11.4 Market Competition News and Trend
  11.4.1 Merger, Consolidation or Acquisition News
  11.4.2 Investment or Disinvestment News
  11.4.3 New Product Development and Launch

CHAPTER 12 BIOSIMILAR INSULIN MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

12.1 Pfizer
  12.1.1 Company profile
  12.1.2 Representative Biosimilar Insulin Product
  12.1.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Pfizer
12.2 Biogenomics
  12.2.1 Company profile
  12.2.2 Representative Biosimilar Insulin Product
  12.2.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Biogenomics
12.3 Eli Lilly
  12.3.1 Company profile
  12.3.2 Representative Biosimilar Insulin Product
  12.3.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Eli Lilly
12.4 Gan&Lee Pharmaceuticals
  12.4.1 Company profile
  12.4.2 Representative Biosimilar Insulin Product
  12.4.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Gan&Lee Pharmaceuticals
12.5 Geropharm
  12.5.1 Company profile
  12.5.2 Representative Biosimilar Insulin Product
  12.5.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Geropharm
12.6 Julphar Gulf Pharmaceutical Industries
  12.6.1 Company profile
  12.6.2 Representative Biosimilar Insulin Product
  12.6.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Julphar Gulf Pharmaceutical Industries
12.7 Paras Biopharmaceuticals
  12.7.1 Company profile
  12.7.2 Representative Biosimilar Insulin Product
  12.7.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Paras Biopharmaceuticals
12.8 Samsung Bioepis
  12.8.1 Company profile
  12.8.2 Representative Biosimilar Insulin Product
  12.8.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Samsung Bioepis
12.9 Sedico
  12.9.1 Company profile
  12.9.2 Representative Biosimilar Insulin Product
  12.9.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Sedico
12.10 Wockhardt
  12.10.1 Company profile
  12.10.2 Representative Biosimilar Insulin Product
  12.10.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Wockhardt
12.11 Teva Pharmaceuticals
  12.11.1 Company profile
  12.11.2 Representative Biosimilar Insulin Product
  12.11.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILAR INSULIN

13.1 Industry Chain of Biosimilar Insulin
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILAR INSULIN

14.1 Cost Structure Analysis of Biosimilar Insulin
14.2 Raw Materials Cost Analysis of Biosimilar Insulin
14.3 Labor Cost Analysis of Biosimilar Insulin
14.4 Manufacturing Expenses Analysis of Biosimilar Insulin

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

16.1 Methodology/Research Approach
  16.1.1 Research Programs/Design
  16.1.2 Market Size Estimation
  16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
  16.2.1 Secondary Sources
  16.2.2 Primary Sources
16.3 Reference


More Publications